Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
ConclusionNotwithstanding limitations, our study found a higher proportion of psychiatric AEs with lorlatinib, but also raised the hypothesis of psychiatric reactions as a class effect of ALK TKIs.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Anxiety | Cancer | Cancer & Oncology | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Psychiatry | Study